May 10, 2012

Jenner & Block Partner Kevin T. Collins was interviewed by The Deal Pipeline on the forces driving pharma M&A at Northwestern Law’s 32nd Annual Ray Garrett Jr. Corporate and Securities Law Institute. In the interview, Mr. Collins explained that the increase in M&A in the pharma sector has been fueled by the expiration of blockbuster drug patents and the melding of generic and branded drug makers.

Mr. Collins represents companies in the life sciences, healthcare, chemical and technology sectors. He counsels clients in connection with SEC registered and privately placed equity and debt financings, mergers and acquisitions, strategic partnering and licensing transactions, corporate governance matters and securities law compliance.

Please click here for full interview.